ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
ProMIS Neurosciences Inc. has appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino brings over 15 years of global biopharmaceutical leadership, with deep expertise in neuroscience and Alzheimer's disease, having previously held senior roles at Biogen and F. Hoffmann-La Roche. Her appointment strengthens the company's commercial and development leadership as its lead Alzheimer's candidate, PMN310, approaches 12-month topline data expected in Q1 2027.
ProMIS Neurosciences names former Biogen executive as chief commercial officer
ProMIS Neurosciences Inc. (PMN) has appointed Ivana Rubino, Ph.D., formerly a Vice President at Biogen, as its new Chief Commercial Officer. In this role, Dr. Rubino will lead the commercial and market preparation strategy for PMN310, ProMIS' investigational antibody for Alzheimer's disease, as the company anticipates 12-month topline results from its Phase 1b clinical study in Q1 2027. She brings extensive experience from Biogen and F. Hoffmann-La Roche AG in medical affairs, commercial, and regulatory capacities.
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
ProMIS Neurosciences has appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino, a former senior Biogen and Roche executive, brings over 15 years of global biopharmaceutical leadership with extensive experience in Alzheimer’s disease clinical development, commercialization, and global medical strategy. Her appointment is expected to strengthen the company's commercial and development leadership as its lead Alzheimer's program, PMN310, advances towards 12-month topline data in Q1 2027.
Biogen (NASDAQ:BIIB) Bets on New Launches to Offset Legacy Pressure
Biogen (NASDAQ:BIIB) is focusing on new product launches and Leqembi adoption to counteract pressures from tight biotech funding and higher interest rates. The company's future hinges on its execution across cost discipline, pipeline readouts, and the performance of its multiple sclerosis franchise. The broader biotechnology sector is also navigating challenges like drug-pricing policies and patent timelines, making established revenue and disciplined spending crucial.
Biogen reports lupus data while Biogen stock trades at EUR 199.33
Biogen stock was trading at EUR 199.33 on October 6, 2026, and new data from its AMETHYST study showed litifilimab significantly improved skin clearance in cutaneous lupus erythematosus patients at Week 52. While the company reported increased revenue, its net profit declined. Analysts maintain a "Buy" rating for Biogen, with a price target above its recent Nasdaq closing price.
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4
Biogen's Chief Accounting Officer Sean Godbout filed a Form 4 detailing his October 2026 equity transactions. These included the grant of 985 restricted stock units, the conversion of 27 RSUs into common stock, and the sale of 8 shares to cover tax withholdings. Following these transactions, Godbout directly held 1,458.9845 shares of Biogen common stock.
Form 4 BIOGEN INC. For: Oct 01 Filed by: Godbout Sean
Sean Godbout, Chief Accounting Officer of Biogen Inc. (BIIB), filed a Form 4 detailing transactions on October 1st and 2nd, 2026. The filing indicates the acquisition of 27 shares of common stock through a derivative transaction and the disposal of 8 shares to cover taxes, resulting in a beneficial ownership of 1,458.9845 shares. Additionally, Godbout was granted 985 restricted stock units on October 1, 2026, vesting in three equal annual installments.
Biogen stock gains 1.56 percent as litifilimab data reach Week 52
Biogen stock rose 1.56 percent to USD 223.32 after its litifilimab drug achieved a 27.2 percent response rate at Week 52 in a Phase 2 study for cutaneous lupus. The company also reported a 3.4 percent increase in Q2 revenue to USD 2.736 billion, though GAAP diluted EPS fell significantly. Analysts maintain a "Buy" rating with an average target price suggesting limited upside.
Stoke Therapeutics aligns with FDA on zorevunersen NDA submission
Stoke Therapeutics announced alignment with the FDA on the New Drug Application (NDA) submission for zorevunersen, an investigational treatment for Dravet syndrome. The company discussed five years of clinical data and received FDA feedback on submission timing, data, and analysis methods. Stoke plans to submit data through the first half of 2027, following the Phase 3 readout, with the full NDA submission targeted for the second half of 2027.
Biogen reports litifilimab data and Jefferies keeps Buy on Biogen stock
Biogen (BIIB) reported 52-week data for its drug litifilimab, showing improved skin clearance in psoriasis patients, while Jefferies maintained a Buy rating with a $255 price target. The company's second-quarter 2026 revenue increased to $2.74 billion, but net profit fell significantly. Biogen's stock was trading at EUR 195.62, and its next earnings report is anticipated on October 28, 2026.
NC State honors Agilent’s Joydeep Ganguly for professional achievement
North Carolina State University’s Poole College of Management has honored Joydeep Ganguly, an NC State MBA graduate and Chief Operations and Quality Officer at Agilent Technologies, with its Professional Achievement Award. Ganguly was recognized for his global manufacturing innovation and operational leadership, overseeing a $7B+ revenue enterprise with 23+ manufacturing sites and serving customers across 110 countries. He also contributes to social impact through past board roles at the Gilead and Biogen Foundations and remains engaged with NC State by serving on its Operations and Technology Program Advisory Council.
Audited Vidya accounts for 2024 and 2025 join Processa (PCSA)'s acquisition update.
Processa Pharmaceuticals (PCSA) has updated its acquisition details for Vidya Therapeutics, including Vidya's audited financial statements for 2024 and 2025 and unaudited interim statements for the first half of 2026. This amendment is part of the 8-K filing related to Processa's acquisition of Vidya, which closed on July 28, 2026, bringing the BTK inhibitor VT7208 into Processa's pipeline. The updated filing provides financial context for the acquisition and Processa's pro forma financial information, highlighting the company's focus on developing VT7208 for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis.
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Stoke Therapeutics has completed a successful meeting with the FDA to align on its planned U.S. New Drug Application (NDA) for zorevunersen, a potential treatment for Dravet syndrome. The company will use a multicomponent assessment of four Vineland-3 subdomains to evaluate changes in cognition and behavior in the Phase 3 EMPEROR study. Stoke anticipates a Phase 3 readout in Q3 2027 and plans to complete the NDA submission in Q4 2027, aiming for potential U.S. approval and launch in early 2028.
Biogen’s litifilimab builds momentum with durable 52-week responses in CLE
Biogen (Nasdaq: BIIB) has reported positive 52-week Phase II data for litifilimab in cutaneous lupus erythematosus (CLE) from its AMETHYST study, showing durable responses with 27.2% of participants achieving clear or almost clear skin. This represents an increase from 19.0% at Week 24, highlighting the drug's sustained efficacy in an area with no approved targeted therapies. The US FDA granted Breakthrough Therapy Designation to litifilimab for CLE in January 2026, and blinded Phase III results are anticipated in the first half of 2027.
Precision Medicine: A 62-Asset Test Of Whether The Vertex Model Travels Beyond Oncology
In Vivo has identified 62 non-oncology precision medicine assets currently undergoing clinical trials, with gene therapy being the predominant intervention. This analysis explores whether the successful Vertex Pharmaceuticals model, known for its precision medicine approach in oncology, can be effectively applied to other therapeutic areas. The article examines the implications of this finding for the broader life sciences industry.
Biogen stock reports durable lupus data as Q3 date nears
Biogen (BIIB) stock closed at USD 219.88 after new litifilimab data showed 27.2 percent skin clearance at Week 52 in cutaneous lupus, with Q3 results approaching on October 28. Despite a fall in net income and diluted EPS in Q2 2026 due to acquisition and restructuring charges, revenue grew 3.4 percent year-over-year. Analysts remain optimistic with a "Buy" rating and an average price target of USD 238.22, indicating potential upside.
Alpha Cognition Inc. Common Stock (ACOG) Stock Price, News, Quote & History
This article provides detailed financial information and an overview of Alpha Cognition Inc. (ACOG), a biopharmaceutical company focused on neurodegenerative diseases. It includes stock performance data, analyst insights, earnings trends, and company profile details, highlighting their development programs for Alzheimer's and other neurological conditions.
Biogen Inc. Announces 52-Week Results From The Phase 2 Part Of The Ongoing AMETHYST Phase 2/3 Study Of Litifilimab In Cutaneous Lupus Erythematosus
Biogen Inc. announced positive 52-week results from the Phase 2 portion of the AMETHYST study for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating rapid and durable improvements in skin disease activity. Participants treated with litifilimab showed continued clinical improvements, with those switching from placebo experiencing rapid benefits. The drug, which received FDA Breakthrough Therapy Designation, was generally well tolerated with a safety profile consistent with previous studies.
Biogen phase 2 litifilimab data boosts lupus candidate
Long-term phase 2 data for Biogen's litifilimab showed promising results for cutaneous lupus erythematosus. After one year, patients achieved clear skin and reduced disease activity. This data comes from the AMETHYST Phase 2/3 trial, supporting the candidate's potential.
Nasdaq Pops After Jobs Report; Arrow, Materion, Advantest In Focus
Alissa Coram and Justin Nielsen discuss Friday's market action and key stocks including Arrow, Materion, and Advantest, as the Nasdaq sees a pop after the latest jobs report. This video provides insights into the current market trends and highlights specific companies attracting investor attention. The article provides a transcript and additional related video content.
Biogen's experimental lupus drug shows benefit against skin symptoms
Biogen's experimental lupus drug has demonstrated positive results in treating skin symptoms associated with lupus. The article, sourced from Reuters, suggests that the drug is still in its experimental phase. Readers can access the full article on TradingView.
Biogen's experimental lupus drug shows benefit against skin symptoms
Biogen announced that its experimental drug, litifilimab, demonstrated durable improvement in skin symptoms for patients with cutaneous lupus erythematosus (CLE) in a mid-stage study. The drug, which targets BDCA2 receptors to suppress inflammation, showed that 27.2% of participants achieved clear or almost clear skin after one year, with no new safety concerns identified. These results are crucial for Biogen as it seeks to diversify its product portfolio amidst challenges to its multiple sclerosis treatments.
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Biogen announced 52-week results from the Phase 2 part of the AMETHYST study for litifilimab in cutaneous lupus erythematosus (CLE), showing continued improvements in skin disease activity and rapid onset of effect for those who switched from placebo. The drug demonstrated a consistent safety profile, with more than a quarter of participants achieving clear or almost clear skin by Week 52. These results reinforce litifilimab's potential as a first-in-class, targeted therapy for CLE, a condition for which it received Breakthrough Therapy Designation in January 2026.
Biogen reports 52-week litifilimab data for lupus treatment
Biogen (NASDAQ:BIIB) has announced 52-week results from the Phase 2 AMETHYST study of litifilimab for cutaneous lupus erythematosus (CLE). The data showed improvements in skin disease activity, with 27.2% of initial participants achieving clear or almost clear skin by week 52, and 33.7% of those who switched from placebo to litifilimab also showing significant improvement. The drug was generally well-tolerated, and the Phase 3 study results are anticipated in the first half of 2027, as there are currently no approved targeted therapies for CLE.
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Biogen announced 52-week results from the Phase 2 part of the AMETHYST study for litifilimab in cutaneous lupus erythematosus (CLE), showing continued and rapid improvements in skin disease activity. Participants on litifilimab saw increased response rates, with those switching from placebo experiencing rapid onset of effect. The safety profile remained consistent with previous studies, and Phase 3 results are anticipated in the first half of 2027.
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
AbbVie (ABBV) has received FDA approval for Juvmo, a new once-daily oral treatment for Parkinson's disease, with a commercial launch planned for October 2026. This drug, the first selective D1/D5 dopamine receptor agonist, is expected to significantly boost AbbVie's neuroscience franchise, which already includes Vyalev and Duopa, aiming for over $5 billion in peak sales from these therapies. The approval also validates AbbVie's 2024 acquisition of Cerevel Therapeutics, despite previous setbacks with other assets from the deal.
United Therapeutics Jumps 13% After Court Backs Key Patent Claims Against Liquidia
United Therapeutics shares surged 13% after a Delaware federal judge ruled that Liquidia's Yutrepia infringed two valid patent claims related to inhaled treprostinil for PH-ILD, causing Liquidia's stock to drop over 50%. The court invalidated four other claims, and both companies have one week to propose remedies, with United Therapeutics seeking withdrawal of Yutrepia's approval and damages, while Liquidia plans to appeal. An analyst upgraded United Therapeutics to Buy with a $728 target following the decision.
6,494 The Sherwin-Williams Company $SHW Shares Sold by Confluence Investment Management LLC
Confluence Investment Management LLC has reduced its stake in The Sherwin-Williams Company (SHW) by 10.4%, selling 6,494 shares, but still holds 55,762 shares valued at $18 million. Institutional investors own 77.67% of SHW, which recently reported strong quarterly results and maintains a quarterly dividend. Analysts have a "Moderate Buy" rating, and the company is expanding its manufacturing capacity in North Carolina to support future growth.
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Unicycive Therapeutics, a clinical-stage biotechnology company, announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. Manning brings over 25 years of global biopharmaceutical experience, including leadership roles in commercialization and product launches at companies like Soleno Therapeutics and PharmaEssentia Corporation. Her expertise is expected to be invaluable as Unicycive advances its lead investigational treatment, oxylanthanum carbonate, towards potential approval and prepares for commercial-stage growth.
Capricor Therapeutics Shares Jump as Two-Year Data Bolster Duchenne Drug Case
Capricor Therapeutics shares surged after presenting positive 24-month data from its Phase 3 HOPE-3 trial for deramiocel, a Duchenne muscular dystrophy drug. The data showed a significant slowing of upper-limb function decline, leading B. Riley to upgrade the stock to Buy with a raised price target. The results support an amended Biologics License Application, with the FDA extending its review period to November 22nd.
Morgan Stanley Names 3 Biotech Breakthroughs That Offer Investment Opportunities
Morgan Stanley has identified three significant biotech breakthroughs that present investment opportunities: Alzheimer's drugs, gene editing, and artificial intelligence (AI). The bank forecasts the Alzheimer's drug market at $70 billion and a $10 billion in-vivo gene editing market by 2035. For AI, Morgan Stanley favors companies supplying data, tools, and computing power, rather than drug developers, due to the unproven nature of AI raising drug success rates.
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
Pliant Therapeutics has announced the appointment of David Raben, M.D., as its new Chief Medical Officer. Dr. Raben brings over 30 years of experience in academic research, clinical care, and oncology drug development, having previously held senior roles at Bicara Therapeutics, Amgen, and Genentech. His expertise in advancing targeted oncology therapies will be crucial as Pliant Therapeutics progresses its lead program, PLN-101095, through clinical trials.
NeOnc Technologies Holdings (Nasdaq:NTHI) - Stock Analysis
NeOnc Technologies Holdings (NTHI), a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. The company recently reported promising Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma, showing significant progression-free survival and median overall survival. Additionally, NTHI announced an upcoming FDA meeting for NEO212, a conjugated chemotherapy, and has been involved in several insider stock transactions and funding rounds.
HPE Stock Jumps As AI Deals And Guidance Ignite Momentum
Hewlett Packard Enterprise (HPE) stock surged over 6% following robust Q3 FY26 results, driven by significant growth in its AI and networking divisions. The company announced a $3.5 billion AI inferencing contract and expanded its partnership with Oracle, leading analysts to raise price targets. HPE's strong financial performance, increased guidance, and strategic positioning in the AI infrastructure build-out have ignited significant market momentum.
Invivyd’s Covid-directed mAb hits Phase III safety goals
Invivyd's VYD2311, a Covid-targeting monoclonal antibody, demonstrated superior safety and tolerability compared to Pfizer and BioNTech's Comirnaty in a Phase III study. Despite meeting co-primary safety endpoints, the company's shares slumped due to a delayed topline readout for a separate study. Invivyd plans to submit a Biologics License Application for VYD2311 pending further trial results, aiming to offer a new Covid-19 protection option amidst growing public skepticism towards existing vaccines.
Transcript: Niagen Bioscience Q2 2026 Earnings Conference Call
Niagen Bioscience reported Q2 2026 revenue of $29.8 million, with Tru Niagen sales up 6% year-over-year, driven by a 14% increase in e-commerce. The company is expanding beyond supplements into skincare and pharmaceuticals, launching NAD Pharmaceuticals and developing NB4168 for rare genetic diseases, and is also targeting the IV and injection markets with Niagen Plus. Management highlighted the resilience of its core business and expressed confidence in multiple long-term growth engines while maintaining financial discipline and a strong balance sheet.
Travere Therapeutics (TVTX) Secures FILSPARI Patent Extension, Is The Stock A Bargain?
Travere Therapeutics (TVTX) recently secured a patent extension for its drug FILSPARI, now protected until October 2037 for focal segmental glomerulosclerosis. Despite mixed short-term stock performance, the company shows strong long-term sentiment and is considered 19% undervalued by many, with a fair value pegged at $74.14. However, a different valuation perspective, using sales multiples, suggests the stock might be richly priced compared to peers, indicating less room for error if the FILSPARI thesis faces challenges.
Has Mesoblast (ASX:MSB) Cleared a Key FDA Manufacturing Hurdle for Ryoncil?
Mesoblast has secured FDA approval for a new potency assay (TIBA) for its cell therapy Ryoncil, which is crucial for ensuring consistent product quality in commercial batches. This approval addresses a significant hurdle in cell therapy manufacturing by allowing the company flexibility to scale production or change facilities while maintaining FDA compliance. While important for operational efficiency, the article notes that larger drivers for Mesoblast's stock will be Ryoncil sales growth, adult label expansion, and upcoming late-stage pipeline readouts.
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial
Amgen is preparing its rare disease asset daxdilimab for Phase III trials in discoid lupus, following positive mid-stage results. The drug, acquired through the Horizon purchase, targets a condition affecting approximately 28 out of every 100,000 people in the US. This move signals Amgen's advancement in the immune disorders therapeutic area.
Biogen stock after-hours at EUR 200.20: minus 0.22 percent versus prior close
Biogen's stock closed after-hours at EUR 200.20, marking a 0.22 percent decrease compared to its prior close. Recent company updates include the Japanese approval of LEQEMBI Pen for early Alzheimer’s disease and positive results from the VALIANT study's adolescent subgroup analysis for EMPAVELI. Biogen is scheduled to release its third-quarter 2026 financial results on October 28, 2026.
Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency
Prime Medicine (Nasdaq: PRME) has received FDA clearance for PM647, a one-time in vivo prime editing therapy for alpha-1 antitrypsin deficiency (AATD). This therapy aims to correct the genetic defect, addressing both lung and liver manifestations with a single treatment. Initial clinical data are anticipated in 2027, placing PM647 in a competitive field of genetic medicines for AATD.
NeuroSense Therapeutics Ltd. (NRSN) Stock Price, News, Quote & History
This article provides a detailed overview of NeuroSense Therapeutics Ltd. (NRSN), a clinical-stage biotechnology company focused on neurodegenerative diseases. It covers the company's stock performance, key financial metrics, product pipeline including PrimeC for ALS and Alzheimer's, and recent analyst ratings. The stock experienced significant gains over the past year but showed a slight drop in pre-market trading.
How At Home Alzheimer’s Treatment Could Impact Biogen (BIIB) Investors
Biogen recently announced two key product updates: positive Phase 3 trial results for EMPAVELI in rare kidney diseases and Japanese approval of LEQEMBI Pen, an at-home subcutaneous treatment for early Alzheimer's. The LEQEMBI Pen's convenience could significantly improve patient access and uptake for Biogen's Alzheimer's franchise. These developments aim to strengthen Biogen's shift towards a broader neurology and rare disease portfolio, with LEQEMBI remaining a critical growth driver for investors.
Biogen stock at USD 228.69 on September 28, 2026
Biogen stock closed at USD 228.69 on September 28, 2026, marking a 0.48 percent increase. The company recently published pediatric EMPAVELI data showing significant proteinuria reduction in adolescents and plans to release its third-quarter 2026 financial results on October 28, 2026.
Biogen Inc. (BIIB) Stock Price, News, Quote & History
This page provides an overview of Biogen Inc. (BIIB) stock, including its current price, recent news headlines, and performance data. It highlights articles discussing Biogen's growth portfolio, Q2 earnings, advancements in therapeutics, and recent trial data for kidney disease and Dravet syndrome. The performance overview shows Biogen's trailing total returns against the S&P 500 benchmark.
PTC Therapeutics Jumps 5.5% Amid Sector-Wide Rally
PTC Therapeutics (PTCT) saw its stock jump 5.5% on Monday, closing at $66.13, as part of a broad sector-wide rally in biotechnology stocks. The gain was attributed to overall investor momentum and a shift in risk appetite towards biotech, rather than any company-specific news or developments. Other sector peers like GRAL and TVTX also experienced similar gains, suggesting a collective movement within the industry.
AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start
AbbVie recently received FDA approval for its new Parkinson's pill, Juvmo (tavapadon), which is expected to be available to U.S. patients in October 2026. Despite this approval, management anticipates a slow start for the drug due to missing the Medicare reimbursement window for 2027. AbbVie projects its Parkinson's franchise to reach $5 billion in peak sales, driven by Juvmo and other therapies like Vyalev.
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
Biogen is undergoing a significant transformation, with its growth product portfolio now surpassing revenues from its legacy multiple sclerosis (MS) drugs. This shift was evident in Q2 2026 results, where growth products generated $1.06 billion compared to $767 million from the MS portfolio, driven by new drugs like Skyclarys, Qalsody, Zurzuvae, Spinraza, and recently acquired assets from Apellis, as well as the Leqembi collaboration. The company expects this trend to continue, with international expansion and commercial execution driving future growth.
Biogen stock closes 0.55 percent higher as Q2 growth holds
Biogen (BIIB) stock closed 0.55% higher on September 25, 2026, at USD 227.60, with its Q2 2026 revenue reaching USD 2.74 billion, exceeding expectations by USD 0.28 billion. The company reported adjusted EPS of USD 3.60, beating the consensus by USD 0.66, indicating a strong earnings base. Analysts maintain a "Moderate Buy" rating with a 12-month price target of USD 230.14, and Biogen is set to release its Q3 2026 financial results on October 28, 2026.
Silexion reports preclinical data on SIL204 delivery mechanism
Silexion Therapeutics Corp. announced preclinical findings that its lead drug candidate, SIL204, utilizes naturally occurring lipoproteins in blood serum for cellular entry to silence the KRAS oncogene in cancer cells. This mechanism, which doesn't require synthetic transfection reagents, targets the upregulated LDL receptor in cancer cells. The company is currently conducting a Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer and further preclinical studies are ongoing.
